Publication: Exendin-4 as a versatile therapeutic agent for the amelioration of diabetic changes
dc.contributor.coauthor | Ahmadi, Mahdi | |
dc.contributor.coauthor | Aslani, Somayeh | |
dc.contributor.coauthor | Saberianpour, Shirin | |
dc.contributor.coauthor | Rahbarghazi, Reza | |
dc.contributor.kuauthor | Rajabi, Hadi | |
dc.contributor.kuprofile | Faculty Member | |
dc.contributor.researchcenter | Koç University Research Center for Translational Medicine (KUTTAM) / Koç Üniversitesi Translasyonel Tıp Araştırma Merkezi (KUTTAM) | |
dc.contributor.schoolcollegeinstitute | Graduate School of Health Sciences | |
dc.date.accessioned | 2024-11-09T12:12:19Z | |
dc.date.issued | 2022 | |
dc.description.abstract | Type 2 diabetes mellitus (T2DM) is a chronic metabolic abnormality leading to microvascular and macrovascular complications. Non-insulin Incretin mimic synthetic peptide exendin-4 was introduced as an anti-diabetic drug which helped diabetic patients with triggering insulin secretion; further researches have revealed an effective role of exendin-4 in treatment of T2DM related diseases. Exendin-4 is approximately similar to Glucagon like peptide, thus it can bind to the glucagon-like peptide-1 receptor (GLP-1R) and activated different signaling pathways that are involved in various bioactivides such as apoptosis, insulin secretion and inactivation of microglial. In this review, we investigated the interesting role of exendin-4 in various kinds of T2DM related disorders through the activation of different signaling pathways. | |
dc.description.fulltext | YES | |
dc.description.indexedby | WoS | |
dc.description.indexedby | Scopus | |
dc.description.indexedby | PubMed | |
dc.description.issue | 2 | |
dc.description.openaccess | YES | |
dc.description.publisherscope | International | |
dc.description.sponsoredbyTubitakEu | N/A | |
dc.description.sponsorship | N/A | |
dc.description.version | Publisher version | |
dc.description.volume | 12 | |
dc.format | ||
dc.identifier.doi | 10.34172/apb.2022.025 | |
dc.identifier.eissn | 2251-7308 | |
dc.identifier.embargo | NO | |
dc.identifier.filenameinventoryno | IR03520 | |
dc.identifier.issn | 2228-5881 | |
dc.identifier.link | https://doi.org/10.34172/apb.2022.025 | |
dc.identifier.quartile | N/A | |
dc.identifier.scopus | 2-s2.0-85128166956 | |
dc.identifier.uri | https://hdl.handle.net/20.500.14288/1154 | |
dc.identifier.wos | 768125100004 | |
dc.keywords | Diabetes complications | |
dc.keywords | Exendin-4 | |
dc.keywords | Signaling pathways | |
dc.language | English | |
dc.publisher | Tabriz University of Medical Sciences | |
dc.relation.grantno | NA | |
dc.relation.uri | http://cdm21054.contentdm.oclc.org/cdm/ref/collection/IR/id/10315 | |
dc.source | Advanced Pharmaceutical Bulletin | |
dc.subject | Pharmacology and pharmacy | |
dc.title | Exendin-4 as a versatile therapeutic agent for the amelioration of diabetic changes | |
dc.type | Review | |
dspace.entity.type | Publication | |
local.contributor.kuauthor | Rajabi, Hadi |
Files
Original bundle
1 - 1 of 1